Aquestive Therapeutics, Inc. january 16, 2026 Please complete the form below to contact Kaplan Fox regarding the Aquestive Therapeutics Investigation: Join a Case First Name * Last Name * Email Address * Phone Number * Ticker Symbol Or Company Name * Please Insert Your Estimation Of Losses In USD * Are you a current or former employee of the company mentioned having traded above? * Yes No Captcha Submit If you are human, leave this field blank. Principle Contacts Jeffrey P. Campisi JCampisi@kaplanfox.comLaurence D. KingLKing@kaplanfox.com Kaplan Fox & Kilsheimer LLP is Investigating Aquestive Therapeutics, Inc. (AQST) for Potential Securities Law Violations Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you have information that could assist in the Aquestive investigation or you are an investor in Aquestive and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing jcampisi@kaplanfox.com or by calling (212) 329-8571. Aquestive is a pharmaceutical company, focusing on late-stage treatment of central nervous system diseases. The Company is developing Anaphylm, an oral medication designed to treat anaphylaxis and other severe allergic reactions. On January 9, 2026, before market hours, Aquestive announced in a press release that they are in “receipt of FDA letter stating it has deficiencies that preclude labeling discussions for Anaphylm at this time.” The President and Chief Executive Officer, Dan Barber, further stated that “[a]s part of its ongoing review of the Company’s NDA for Anaphylm, the FDA notified us that it had identified deficiencies in the NDA that preclude discussion of labeling and post-marketing commitments at this time.” Following this news, the price of Aquestive stock declined from a closing price on January 8, 2025 of $6.21 per share, to close at $3.91 per share on January 9, 2025, a decline of $2.30 per share, or 37.04%. WHY CONTACT KAPLAN FOX Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this Notice, your rights, or your interests, please contact: CONTACT:Jeffrey P. CampisiKAPLAN FOX & KILSHEIMER LLP800 Third Avenue, 38th FloorNew York, New York 10022(212) 329-8571jcampisi@kaplanfox.com Laurence D. KingKAPLAN FOX & KILSHEIMER LLP1999 Harrison Street, Suite 1501Oakland, California 94612(415) 772-4704lking@kaplanfox.com The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client. Any information you submit will be maintained as confidential. If Kaplan Fox, in its sole discretion, believes that you might be an appropriate client, Kaplan Fox will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases. Connect with Kaplan Fox. Receive a complimentary case review now. Contact Us Beyond Meat, Inc. See the Case BlackRock TCP Capital Corp. See the Case Commvault Systems, Inc. See the Case REGENXBIO Inc. See the Case Navan, Inc. See the Case Nutanix, Inc. See the Case Lakeland Industries, Inc. See the Case BellRing Brands, Inc. See the Case Bath & Body Works, Inc. See the Case Gibraltar Industries, Inc. See the Case Wealthfront Corporation See the Case Chagee Holdings Limited See the Case
